Trends in Platelet Adenosine Diphosphate P2Y12 Receptor Inhibitor Use and Adherence Among Antiplatelet-Naive Patients After Percutaneous Coronary Intervention, 2008-2016
Sign Up to like & getrecommendations! Published in 2018 at "JAMA Internal Medicine"
DOI: 10.1001/jamainternmed.2018.0783
Abstract: Importance Current guidelines recommend prasugrel hydrochloride and ticagrelor hydrochloride as preferred therapies for patients with acute coronary syndrome (ACS) treated with percutaneous coronary intervention (PCI). However, it is not well known how frequently these newer… read more here.
Keywords: iqr; inhibitor; p2y12; ticagrelor ... See more keywords
Comparative Risk of Hospitalized Bleeding of P2Y12 Inhibitors for Secondary Prophylaxis in Acute Coronary Syndrome After Percutaneous Coronary Intervention
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Pharmacology and Therapeutics"
DOI: 10.1002/cpt.2806
Abstract: In closely monitored randomized controlled trials (RCTs), newer P2Y12 agents (ticagrelor and prasugrel) reduced cardiovascular outcomes compared with clopidogrel following percutaneous coronary intervention (PCI) in acute coronary syndrome. However, these RCTs indicated a higher bleeding… read more here.
Keywords: p2y12; major bleeding; prasugrel; clopidogrel ... See more keywords
Contemporary use of P2Y12 inhibitors in patients with ST-segment elevation myocardial infarction referred to primary percutaneous coronary interventions in Poland: Data from ORPKI national registry
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Thrombosis and Thrombolysis"
DOI: 10.1007/s11239-017-1579-9
Abstract: According to guidelines, it is recommended to give P2Y12 inhibitors (preferably ticagrelor or prasugrel) at the time of first medical contact in patients with STEMI. However, in real life antiplatelet treatment strategies are different among… read more here.
Keywords: ticagrelor prasugrel; registry; p2y12 inhibitors; p2y12 ... See more keywords
Toward Brief Dual Antiplatelet Therapy and P2Y12 Inhibitors for Monotherapy After PCI
Sign Up to like & getrecommendations! Published in 2020 at "American Journal of Cardiovascular Drugs"
DOI: 10.1007/s40256-020-00430-0
Abstract: The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention remains a controversial topic. The European Society of Cardiology and the American College of Cardiology/American Heart Association recommend at least 6 and 12… read more here.
Keywords: cardiology; antiplatelet; dual antiplatelet; antiplatelet therapy ... See more keywords
Efficacy and safety of potent platelet P2Y12 receptor inhibitors in elderly versus nonelderly patients with acute coronary syndrome: A systematic review and meta‐analysis
Sign Up to like & getrecommendations! Published in 2018 at "American Heart Journal"
DOI: 10.1016/j.ahj.2017.09.012
Abstract: Background The use of the potent oral P2Y12 inhibitors prasugrel and ticagrelor in patients with acute coronary syndromes (ACS) has a favorable net clinical effect compared with clopidogrel and is recommended as first‐line therapy. However,… read more here.
Keywords: p2y12; safety; efficacy; nonelderly patients ... See more keywords
Genetic Determinants of P2Y12 Inhibitors and Clinical Implications.
Sign Up to like & getrecommendations! Published in 2017 at "Interventional cardiology clinics"
DOI: 10.1016/j.iccl.2016.08.010
Abstract: There is significant interpatient variability in clopidogrel effectiveness, which is due in part to cytochrome P450 (CYP) 2C19 genotype. Approximately 30% of individuals carry CYP2C19 loss-of-function alleles, which have been consistently shown to reduce clopidogrel… read more here.
Keywords: genetic determinants; cardiology; clinical implications; inhibitors clinical ... See more keywords
Comparison of prescription rates and clinical outcomes in acute coronary syndrome patients who underwent percutaneous coronary intervention using different P2Y12 inhibitors in a large observational study.
Sign Up to like & getrecommendations! Published in 2019 at "International journal of cardiology"
DOI: 10.1016/j.ijcard.2018.09.011
Abstract: BACKGROUND To compare the prescription rates, safety, and efficacy of contemporary P2Y12 inhibitors in acute coronary syndrome (ACS) patients following percutaneous coronary intervention (PCI). METHODS From 9684 ACS patients who underwent PCI in a nationwide,… read more here.
Keywords: ticagrelor prasugrel; acute coronary; prescription rates; p2y12 inhibitors ... See more keywords
Association Between Ischemic and Bleeding Risk Scores and the Use of New P2Y12 Inhibitors in Patients With Acute Coronary Syndrome.
Sign Up to like & getrecommendations! Published in 2018 at "Revista espanola de cardiologia"
DOI: 10.1016/j.rec.2017.10.009
Abstract: INTRODUCTION AND OBJECTIVES Acute coronary syndrome (ACS) guidelines recommend the use of newer P2Y12 inhibitors (prasugrel and ticagrelor) over clopidogrel in patients with moderate-to-high ischemic risk, unless they have an increased bleeding risk. The aim… read more here.
Keywords: risk; bleeding risk; risk scores; newer p2y12 ... See more keywords
Effect of P2Y12 inhibitors on thrombus stability and endogenous fibrinolysis.
Sign Up to like & getrecommendations! Published in 2019 at "Thrombosis research"
DOI: 10.1016/j.thromres.2018.11.023
Abstract: Although used routinely to reduce thrombotic events in patients with coronary disease, the effects of P2Y12 inhibitors on thrombus stability and endogenous fibrinolysis are largely unknown. Blood taken from patients pre- and post-aspirin (n = 20) and… read more here.
Keywords: thrombus stability; ticagrelor; pre post; cangrelor ... See more keywords
Efficacy and safety of newer P2Y12 inhibitors for acute coronary syndrome: a network meta-analysis
Sign Up to like & getrecommendations! Published in 2020 at "Scientific Reports"
DOI: 10.1038/s41598-020-73871-x
Abstract: Whether newer P2Y12 inhibitors are more efficacious and safer than clopidogrel and whether there is a superior one remain uncertain. We compared the effect of P2Y12 inhibitors on clinical outcomes in patients with acute coronary… read more here.
Keywords: prasugrel; clopidogrel; ticagrelor; acute coronary ... See more keywords
Third-Generation P2Y12 Inhibitors in East Asian Acute Myocardial Infarction Patients: A Nationwide Prospective Multicentre Study.
Sign Up to like & getrecommendations! Published in 2018 at "Thrombosis and haemostasis"
DOI: 10.1055/s-0038-1626697
Abstract: Third-generation P2Y12 inhibitors (prasugrel, ticagrelor) are recommended in acute myocardial infarction (AMI). We aimed to evaluate the efficacy and safety of third-generation P2Y12 inhibitors in East Asian AMI patients. From the Korean AMI Registry, 9,355… read more here.
Keywords: generation p2y12; inhibitors east; p2y12 inhibitors; third generation ... See more keywords